We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+21.87%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$283M
AUM Growth
+$48.4M
Cap. Flow
+$2.2M
Cap. Flow %
0.78%
Top 10 Hldgs %
87.07%
Holding
18
New
1
Increased
3
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$8.28M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.5M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.92M
4
BNTX icon
BioNTech
BNTX
+$2.03M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$8.16M
2
ALKS icon
Alkermes
ALKS
+$3M
3
UTHR icon
United Therapeutics
UTHR
+$2.96M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.43M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$1.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$44.5M 15.71%
91,282
-6,364
-7% -$2.96M
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$366M
$43.6M 15.41%
2,766,390
+651,946
+31% +$8.28M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.6B
$31.2M 11.02%
524,786
+119,336
+29% +$6.5M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$28.5M 10.08%
167,816
– –
EXEL icon
5
Exelixis
EXEL
$13.3B
$21.6M 7.64%
493,526
-25,000
-5% -$1.03M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$18.4M 6.51%
855,860
-100,000
-10% -$1.94M
SNY icon
7
Sanofi
SNY
$103B
$15.7M 5.54%
323,946
– –
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.59B
$15.6M 5.5%
313,499
-49,980
-14% -$2.43M
CAH icon
9
Cardinal Health
CAH
$53.9B
$15.2M 5.35%
73,745
– –
INDV icon
10
Indivior Pharmaceuticals
INDV
$4.73B
$12.2M 4.3%
339,532
– –
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$307M
$10.4M 3.68%
1,180,388
– –
BNTX icon
12
BioNTech
BNTX
$22.9B
$9.47M 3.35%
99,523
+20,157
+25% +$2.03M
GSK icon
13
GSK
GSK
$104B
$4.74M 1.68%
96,729
-175,000
-64% -$8.16M
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.45B
$3.44M 1.22%
+149,634
New +$4.92M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$78.5B
$3.09M 1.09%
4,000
– –
ALKS icon
16
Alkermes
ALKS
$8.22B
$3.02M 1.07%
107,822
-100,000
-48% -$3M
BIIB icon
17
Biogen
BIIB
$30B
$1.76M 0.62%
10,000
– –
EOLS icon
18
Evolus
EOLS
$385M
$665K 0.23%
100,000
– –

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Krensavage Asset Management held 18 positions worth $283M, up 21% from $235M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Krensavage Asset Management's Q4 2025 filing shows 1 new, 3 increased and 6 reduced positions. Its largest new stake was Ultragenyx Pharmaceutical: 149,634 shares worth $3.44M. The largest sale was GSK, an estimated $8.16M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Krensavage Asset Management's largest Q4 2025 buy was Ultragenyx Pharmaceutical: 149,634 shares worth $3.44M.
  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q4 2025, an estimated $8.28M increase.
  • Krensavage Asset Management's biggest Q4 2025 reduction was GSK, cutting an estimated $8.16M.
  • Krensavage Asset Management's ten largest holdings make up 87% of its $283M portfolio in Q4 2025.
  • Krensavage Asset Management opened 1 new position and closed 0 in Q4 2025.
  • Krensavage Asset Management's portfolio value rose 21% quarter-over-quarter to $283M.

Based on Krensavage Asset Management's 13F filing for Q4 2025, filed 18 Feb 2026.